POS0381 GLOBAL, REGIONAL AND NATIONAL BURDEN OF COMORBIDITY FOR OSTEOARTHRITIS, 1990–2019: FINDINGS FROM THE GLOBAL BURDEN OF DISEASE STUDY 2019
Authors: H. Chen, Z. Zhou, K. MA, P. Cao, H. Cen, S. Tang, Y. He, V. Duong, L. Si, D. Hunter, C. Ding, Z. Zhu
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Investigating osteoarthritis (OA) comorbidity can help to elaborate on interrelated causal mechanisms, complexities and considerations involved in person-centered condition management, thereby furthering our understanding of the burden of OA [1]. However, the research on the burden of OA comorbidity is still in its early stages and there is a lack of sufficient evidence [2]. <h3>Objectives:</h3> To estimate the burden of comorbidity in OA, including communicable, maternal, neonatal, and nutritional diseases, non-communicable diseases, and injuries, over a 30-year period. <h3>Methods:</h3> The burden of comorbidity in OA was analyzed using data on age-standardized prevalence rates and disability weights (DWs) averaged to calculate age-standardized years lived with disability (YLDs) rates, based on the Global Burden of Disease (GBD) 2019 Study. A modified formula, utilizing the GBD calculator, was employed to determine the age-standardized YLD rates for the coexistence of OA with 166 other level 3 diseases by year, gender and geographical location. The formula also incorporated specific multipliers to assess deviations from independence. <h3>Results:</h3> Globally, oral disorders were the leading comorbidities in OA, followed by headache disorders and tuberculosis in 1990 (age-standardized comorbidity YLDs rate 117.04, 106.28, 74.23 per 100,000, respectively). In 2019, the top three comorbidities in OA were oral disorders, headache disorders, and age-related and other hearing loss (age-standardized comorbidity YLDs rate 118.89, 110.19, 71.04 per 100,000, respectively). Among the leading 25 comorbidities in OA, the age-standardized comorbidity YLDs rates for diabetes mellitus, other musculoskeletal disorders, and chronic kidney disease exhibited the most significant rise, with a percentage change of 53.21%, 36.07%, and 16.44%, respectively from 1990 to 2019. Vitamin A deficiency, intestinal nematode infections, and tuberculosis exhibited the most significant decrease, with a percentage change of -57.91%, -46.69%, and -24.61%, respectively, from 1990 to 2019 (Figure 1). Over the last three decades, the leading comorbidities in OA were oral disorders in males and gynecological diseases in females. The ranking of comorbidities in OA varied across regions with different socio-demographic indices (SDIs). In countries with high SDI, the top three comorbidities in OA were headache disorders, oral disorders, and low back pain (age-standardized comorbidity YLDs rate 124.31, 111.99, 93.20 per 100,000, respectively). On the other hand, in countries with low SDI, the top three comorbidities were oral disorders, headache disorders, and dietary iron deficiency (age-standardized comorbidity YLDs rate 126.34, 102.62, 97.22 per 100,000, respectively) (Figure 2). <h3>Conclusion:</h3> Globally, the burden of OA comorbidities has risen and varied across regions with different socio-demographic levels. The highest comorbidity burden was due to the coexistence of OA and oral disorders. These findings highlight the significance of addressing the comorbidity burden while tackling the burden of OA. <h3>REFERENCES:</h3> [1] Quicke JG, Conaghan PG, Corp N, Peat G. Osteoarthritis year in review 2021: epidemiology &amp; therapy. Osteoarthritis Cartilage. 2022 Feb;30(2):196-206. [2] Swain S, Sarmanova A, Coupland C, Doherty M, Zhang W. Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken). 2020 Jul;72(7):991-1000. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Zhaohua Zhu: None declared, Haowei Chen: None declared, Zhounan Zhou: None declared, Kang Ma: None declared, Peihua Cao: None declared, Han Cen: None declared, Su'an Tang: None declared, Yan He: None declared, Vicky Duong: None declared, Lei Si: None declared, David Hunter Provides consulting advice on scientific advisory boards for Pfizer, Lilly, TLCBio, Novartis, Tissuegene, Biobone., Changhai Ding: None declared.